IL9 and Parkinson disease: Among the discriminant analytes identified by the PLS-DA model on the basis of inspection of VIP and RP scores, participants with PD showed lower levels of the sEV marker CD9, the mitochondrial subunit NDUFS3, the metabolic modulator FGF21, and the inflammatory cytokine interleukin 9 (IL9).